This company has been acquired
RETA Stock Overview
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Reata Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$172.36 |
| 52 Week High | US$172.46 |
| 52 Week Low | US$21.83 |
| Beta | 1.42 |
| 1 Month Change | 2.05% |
| 3 Month Change | 70.82% |
| 1 Year Change | 581.80% |
| 3 Year Change | 76.92% |
| 5 Year Change | 125.48% |
| Change since IPO | 1,218.75% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
May 10
FDA to not hold advisory committee meeting for Reata Pharma's Friedreich's ataxia drug
Oct 13Will Reata Pharmaceuticals (NASDAQ:RETA) Spend Its Cash Wisely?
Oct 12Reata Pharmaceuticals Q2 2022 Earnings Preview
Aug 05We Think Reata Pharmaceuticals (NASDAQ:RETA) Can Afford To Drive Business Growth
Jun 22Reata Pharmaceuticals: Once Beaten, Twice Shy
Mar 28Reata's Advisory Committee Hiccup Ruins Its Future Prospects
Dec 31Here's Why We're Not Too Worried About Reata Pharmaceuticals' (NASDAQ:RETA) Cash Burn Situation
Dec 23Shareholder Returns
| RETA | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0.09% | 0.9% | 1.2% |
| 1Y | 581.8% | 13.9% | 24.7% |
Return vs Industry: RETA exceeded the US Pharmaceuticals industry which returned 10.9% over the past year.
Return vs Market: RETA exceeded the US Market which returned 15.1% over the past year.
Price Volatility
| RETA volatility | |
|---|---|
| RETA Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: RETA's share price has been volatile over the past 3 months.
Volatility Over Time: RETA's weekly volatility has decreased from 31% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 322 | J. Huff | www.reatapharma.com |
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich’s ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease.
Reata Pharmaceuticals, Inc. Fundamentals Summary
| RETA fundamental statistics | |
|---|---|
| Market cap | US$6.57b |
| Earnings (TTM) | -US$87.62m |
| Revenue (TTM) | US$23.48m |
279.7x
P/S Ratio-74.9x
P/E RatioIs RETA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RETA income statement (TTM) | |
|---|---|
| Revenue | US$23.48m |
| Cost of Revenue | US$204.15m |
| Gross Profit | -US$180.67m |
| Other Expenses | -US$93.05m |
| Earnings | -US$87.62m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.30 |
| Gross Margin | -769.46% |
| Net Profit Margin | -373.18% |
| Debt/Equity Ratio | 83.8% |
How did RETA perform over the long term?
See historical performance and comparison